Shire Continues to Deliver Excellent Growth From Cor...(in inventory ...),Health

Date:10/30/2009

in inventory (11.3) 29.2 (24.2) 39.6 Decrease/(increase) in prepayments and other current assets 25.7 (24.5) (8.1) (0.2) Decrease/(increase) in other assets 0.9 (51.1) 5.3 (53.5) Increase/(decrease) in accounts and notes payable and other liabilities 44.8 131.9 (56.3) 70.7 Returns on investment from joint venture - 7.1 4.9 7.1 Cash flows used in discontinued operations - - (5.9) - Net cash provided by operating activities(A) 134.0 279.4 390.0 525.5 Unaudited US GAAP results for the three months and nine months to September 30, 2009 Consolidated Statements of Cash Flows (continued) 3 months to 3 months to 9 months to 9 months to September September September September 30, 2009 30, 2008 30, 2009 30, 2008 CASH FLOWS FROM INVESTING ACTIVITIES: Movements in restricted cash (3.4) 2.5 (10.1) 7.7 Purchases of subsidiary undertakings and businesses, net of cash acquired - (462.5) (75.5) (462.5) Purchases of non-current investments - (0.2) - (1.3) Purchases of property, plant and equipment (67.5) (77.1) (169.4) (166.5) Purchases of intangible assets (1.0) (25.0) (7.0) (25.0) Proceeds from disposal of non-current investments - - 19.2 10.3 Proceeds from disposal of property, plant and equipment
'/>"/>

SOURCE Shire Plc Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease